<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=791414221315877&amp;ev=PageView&amp;noscript=1">

Med-X Company Updates

Over 1100 Shareholders Have Successfully Accessed Their Med-X Shareholder Dashboard

Posted by Nick Phillips on Nov 10, 2020 3:53:37 PM
In this video, COO and President, Matthew Mills updates everyone on the launch of the new shareholder dashboard. The initial launch on Oct. 21st was a success with over 1,100 shareholders successfully verifying and gaining access to their dashboard.
Read More

Topics: Med-X

 

US Capital Global Engages With Med-X, Inc. as Strategic Advisor for 10MM Capital Formation

Posted by Nick Phillips on Oct 22, 2020 4:29:24 PM
In this video update President and COO, Matthew Mills announces the engagement with Global Capital Group, Year-to-date Revenue Numbers, and how to access the new Med-X Shareholder Dashboard. This update is full of important information so please take the time to read the entire update. Global private financial group, US Capital Global, headquartered in San Francisco engaged by Med-X, Inc., Los Angeles-based green technology manufacturer as a strategic advisor.
Read More

Topics: Med-X

 

Med-X Engages with Eurasian Capital to Support Planned Path to IPO

Posted by Nick Phillips on Sep 16, 2020 10:12:00 AM
In this video update, COO and President, Matthew Mills discusses a new partnership with Eurasian Capital, LLC., shipping to Southeast Asian countries, and year-to-date revenue updates. Progress on the planning of the IPO continues to move forward. We have officially engaged with Eurasian Capital, LLC. Eurasian Capital has a proven track record of handpicking specific high growth companies and supporting their expansion plans by investing and marketing to their network of pension funds, family offices, hedge funds, private equity firms, venture funds, securities analysts (buy-side/sell-side), stockbrokers, and institutional investors.
Read More

 

Med-X Management Team Begins Planning an IPO to Support and Bolster Growth Initiatives

Posted by Nick Phillips on Jul 13, 2020 2:35:00 PM
In this important update, COO and President, Matthew Mills discusses a strategic plan to list the Company on a national exchange to support and bolster the growth of the Nature-Cide and the Thermal-Aid divisions. Matthew Mills also reports on exciting news regarding the Company’s revenue growth, progress with institutional investment firms and the status of the Nature-Cide toxicity testing. Please watch this important announcement. With the recipe of essential products and services, growing revenue, international distribution positioning, all while negotiating with a handful of investment banking firms, the management team has decided to move forward with the plan to execute an Initial Public Offering.
Read More

Topics: Med-X

 

Med-X Launches Regulation CF Crowdfunding Offering on TruCrowd as it Continues to Grow as an Essential Supply Business

Posted by Nick Phillips on Jun 2, 2020 2:39:00 PM
In this video update, COO, Matthew Mills, updates the company shareholders on the continued growth of the Nature-Cide Professional products as well as additional growth on Amazon from our Nature-Cide Ready to Use products. Matthew also announces the launch of an additional capital raising campaign, a Regulation CF Offering, that will offer new potential investors on the TruCrowd platform the opportunity to get involved. In addition, Matthew also discusses the recently filed 1-K Annual Report, progress with toxicity testing and the on-going efforts to bring on institutional investors to advance the company more rapidly. The Full Regulation CF Press Release can be seen at the end of this update.
Read More

Topics: Med-X

 

SEC Extends K1 Filling Deadline Due to Covid-19

Posted by Nick Phillips on Apr 30, 2020 10:29:00 AM
To our Shareholders, In response to the COVID-19 pandemic, we want to share that our focus is on continuing to keep our shareholders informed. In that regard, the Securities and Exchange Commission (“SEC”) earlier this month announced that due to the impact of COVID-19 on businesses, it was providing Regulation A+ companies a 45-day extension to file its Form 1-K Annual Report. Because Med-X personnel and audit personnel are now working remotely as much as possible and relying on our staff to scan and email work papers and other documents, the Company’s ability to complete its audit and file the 2019 Form 1-K prior to its due date is delayed. Notwithstanding the foregoing, the Company expects to file the 2019 Form 1-K shortly but no later than June 13, 2020 (which is 45 days from the 2019 Form 1-K’s original filing deadline of April 29, 2020).
Read More

Topics: Med-X

 

As an Essential Business Med-X Keeps Fulfilling Orders and Continues to Service Customers

Posted by Nick Phillips on Apr 21, 2020 2:45:00 PM
In this update video, President and COO, Matthew Mills, discusses how the company has managed to keep generating revenue during the current California and Los Angeles County Stay-at-Home order, by continuing to fulfill essential business demands. Nature-Cide and Thermal-Aid continue to see a steady amount of orders going out to our multiple distribution partners, as well as facilitating consumers directly via our Amazon FBA positions.
Read More

Topics: Med-X

 

Company Positioned to Sustain Revenue During Covid-19 Pandemic

Posted by Nick Phillips on Mar 19, 2020 2:48:00 PM
In this update COO, Matthew Mills informs the company shareholders that the company has taken the necessary steps and guidance to protect the team members who are working to fulfill orders that continue to come in. Our entire team is safe and we are prepared to do whatever is necessary to protect the company's assets and support the needs of our customers and the community. Seemingly our products continue to carry a popular position, even in difficult times.
Read More

Topics: Med-X

 

$1,000,000 Raised Milestone Reached on the New Offering

Posted by Nick Phillips on Feb 13, 2020 9:11:00 AM
In this update, President & COO, Matthew Mills announces the Company has reached its first crowdfunding capital raising milestone of $1,000,000. He also gives us an update on the acquisition front as well as an important request. The $1,000,000 milestone on any crowdfunding offering is always something to celebrate!! 🙏🎉🎊🎈 We are grateful for all of the shareholders who have participated in the Med-X offerings and excited to see what 2020 has brought so far. We certainly couldn't be seeing brand growth along with green philosophy approaches, that our professional use and consumer customers are practicing daily, without our amazing shareholder’s support!
Read More

Topics: Med-X

 

Two Year Independent Study in Florida Finds Nature-Cide as the Top Performing Pesticide in a Side-by-Side Study Against Top Selling Synthetic Products for Mosquito Control

Posted by Nick Phillips on Jan 17, 2020 9:17:00 AM
It has been a very busy month so far here in Los Angeles. We have a lot to cover and it is important that all shareholders receive this information. In this video update, Matthew brings us up to speed on developments to date in January 2020. Some of the topics Matthew touches on in the video are: Status of the Custom Bed Bug Acquisition. Announcement of Nature-Cide making the shortlist of approved pesticides for the cultivation of industrial hemp in the state of Kentucky. A statement that production begins on CBD Formulation of the Malibu Brands Pacific Pain Relief Cream. The introduction of Bugly, the first at-home retail membership for an all-natural “Do It Yourself” pest control program, that is a private label partnership with Nature-Cide. Journal of the Florida Mosquito Control Association published a study showing the results of a two-year comprehensive study testing the efficacy of 25(b) products alongside the top three global pyrethroid products. The results are astonishing. Status of the pesticide toxicology testing overview. Review of product retail positions and status update on the 2020 inventory needs for all retail brands. Statement regarding Glendale Securities' position with the Company in preparation for the next steps after the potential acquisition. Status of moving the Reg. A+ offering away from StartEngine onto our own independent platform and the launch of a new Regulation Crowdfunding Offering that will be run and overseen by the StartEngine Broker-Dealer Division and run on their platform.
Read More

Topics: Med-X

 

REGULATION A+ Offering is now closed

Recent Posts

Posts by Tag